379 related articles for article (PubMed ID: 29043922)
1. Barriers and facilitators to dispensing of intranasal naloxone by pharmacists.
Bakhireva LN; Bautista A; Cano S; Shrestha S; Bachyrycz AM; Cruz TH
Subst Abus; 2018; 39(3):331-341. PubMed ID: 29043922
[TBL] [Abstract][Full Text] [Related]
2. Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.
Freeman PR; Goodin A; Troske S; Strahl A; Fallin A; Green TC
J Am Pharm Assoc (2003); 2017; 57(2S):S28-S33. PubMed ID: 28139459
[TBL] [Abstract][Full Text] [Related]
3. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
4. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Bailey AM; Wermeling DP
Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
[TBL] [Abstract][Full Text] [Related]
5. Public attitudes and beliefs about Virginia community pharmacists dispensing and administering naloxone.
Haggerty LC; Gatewood SS; Goode JKR
J Am Pharm Assoc (2003); 2018; 58(4S):S73-S77.e1. PubMed ID: 30006189
[TBL] [Abstract][Full Text] [Related]
6. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
7. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
[TBL] [Abstract][Full Text] [Related]
8. Pharmacists' naloxone services beyond community pharmacy settings: A systematic review.
Rawal S; Osae SP; Cobran EK; Albert A; Young HN
Res Social Adm Pharm; 2023 Feb; 19(2):243-265. PubMed ID: 36156267
[TBL] [Abstract][Full Text] [Related]
9. Pharmacist roles, training, and perceived barriers in naloxone dispensing: A systematic review.
Thakur T; Frey M; Chewning B
J Am Pharm Assoc (2003); 2020; 60(1):178-194. PubMed ID: 31371179
[TBL] [Abstract][Full Text] [Related]
10. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
[TBL] [Abstract][Full Text] [Related]
11. Dispensing Naloxone Without a Prescription: Survey Evaluation of Ohio Pharmacists.
Thompson EL; Rao PSS; Hayes C; Purtill C
J Pharm Pract; 2019 Aug; 32(4):412-421. PubMed ID: 29478362
[TBL] [Abstract][Full Text] [Related]
12. A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy.
Sexton SM; Armstrong A; Gatton O; Rhodes LA; Marciniak MW
J Am Pharm Assoc (2003); 2019; 59(4S):S95-S100. PubMed ID: 31231001
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of community pharmacy-based services for type-2 diabetes in an Indonesian setting: pharmacist survey.
Wibowo Y; Parsons R; Sunderland B; Hughes J
Int J Clin Pharm; 2015 Oct; 37(5):873-82. PubMed ID: 25986291
[TBL] [Abstract][Full Text] [Related]
14. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
15. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states.
Green TC; Case P; Fiske H; Baird J; Cabral S; Burstein D; Schwartz V; Potter N; Walley AY; Bratberg J
J Am Pharm Assoc (2003); 2017; 57(2S):S19-S27.e4. PubMed ID: 28214219
[TBL] [Abstract][Full Text] [Related]
16. Pharmacists' experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study.
Pollini RA; Slocum S; Ozga J; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(1):157-166. PubMed ID: 34511372
[TBL] [Abstract][Full Text] [Related]
17. Pharmacy-based statewide naloxone distribution: A novel "top-down, bottom-up" approach.
Morton KJ; Harrand B; Floyd CC; Schaefer C; Acosta J; Logan BC; Clark K
J Am Pharm Assoc (2003); 2017; 57(2S):S99-S106.e5. PubMed ID: 28292508
[TBL] [Abstract][Full Text] [Related]
18. Reviewing state-mandated training requirements for naloxone-dispensing pharmacists.
Roberts AW; Carpenter DM; Smith A; Look KA
Res Social Adm Pharm; 2019 Feb; 15(2):222-225. PubMed ID: 29650444
[TBL] [Abstract][Full Text] [Related]
19. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
Thornton JD; Lyvers E; Scott VGG; Dwibedi N
J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
[TBL] [Abstract][Full Text] [Related]
20. Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural equation modeling approach.
Varisco TJ; Downs CG; Rathburn KR; Fleming ML; Thornton JD
Int J Drug Policy; 2020 Sep; 83():102827. PubMed ID: 32589581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
